S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
NASDAQ:KURA

Kura Oncology Stock Forecast, Price & News

$13.14
-0.50 (-3.67%)
(As of 01/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$12.91
$13.56
50-Day Range
$12.22
$17.88
52-Week Range
$12.02
$36.27
Volume
822,294 shs
Average Volume
580,590 shs
Market Capitalization
$874.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.56
30 days | 90 days | 365 days | Advanced Chart
Receive KURA News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.


Kura Oncology logo

About Kura Oncology

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.

Headlines

Kura Oncology (NASDAQ:KURA) Shares Gap Up to $13.31
January 11, 2022 |  americanbankingnews.com
See Why FDA Hit Red Light On Kura's Early-Stage Leukemia Trial
November 24, 2021 |  markets.businessinsider.com
Why Kura Oncology Stock Is Sliding Today
November 24, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KURA
Fax
N/A
Employees
89
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$10.77 per share

Profitability

Net Income
$-89.63 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
63,295,000
Market Cap
$874.55 million
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
1/19/2022
Next Earnings (Estimated)
2/23/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.63 out of 5 stars

Medical Sector

1010th out of 1,414 stocks

Pharmaceutical Preparations Industry

491st out of 682 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Kura Oncology (NASDAQ:KURA) Frequently Asked Questions

Is Kura Oncology a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Kura Oncology stock.
View analyst ratings for Kura Oncology
or view top-rated stocks.

How has Kura Oncology's stock been impacted by Coronavirus?

Kura Oncology's stock was trading at $9.65 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, KURA shares have increased by 36.2% and is now trading at $13.14.
View which stocks have been most impacted by COVID-19
.

When is Kura Oncology's next earnings date?

Kura Oncology is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Kura Oncology
.

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($0.50) EPS for the quarter, topping the Zacks' consensus estimate of ($0.54) by $0.04. During the same period last year, the firm posted ($0.42) EPS.
View Kura Oncology's earnings history
.

What price target have analysts set for KURA?

5 analysts have issued twelve-month price objectives for Kura Oncology's stock. Their forecasts range from $21.00 to $80.00. On average, they anticipate Kura Oncology's share price to reach $40.00 in the next twelve months. This suggests a possible upside of 204.4% from the stock's current price.
View analysts' price targets for Kura Oncology
or view top-rated stocks among Wall Street analysts.

Who are Kura Oncology's key executives?

Kura Oncology's management team includes the following people:
  • Troy E. Wilson, Chairman, President & Chief Executive Officer
  • Kathleen Ford, Chief Operating Officer
  • Marc Edward Grasso, Chief Financial & Business Officer
  • Stephen Dale, Chief Medical Officer
  • Mollie Leoni, Vice President-Clinical Development

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by a number of retail and institutional investors. Top institutional investors include Lindbrook Capital LLC (0.00%). Company insiders that own Kura Oncology stock include Kathleen Ford, Marc Grasso and Troy Edward Wilson.
View institutional ownership trends for Kura Oncology
.

Which institutional investors are buying Kura Oncology stock?

KURA stock was bought by a variety of institutional investors in the last quarter, including Lindbrook Capital LLC.
View insider buying and selling activity for Kura Oncology
or or view top insider-buying stocks.

How do I buy shares of Kura Oncology?

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $13.14.

How much money does Kura Oncology make?

Kura Oncology has a market capitalization of $874.55 million. The company earns $-89.63 million in net income (profit) each year or ($1.92) on an earnings per share basis.

How many employees does Kura Oncology have?

Kura Oncology employs 89 workers across the globe.

What is Kura Oncology's official website?

The official website for Kura Oncology is www.kuraoncology.com.

Where are Kura Oncology's headquarters?

Kura Oncology is headquartered at 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The company can be reached via phone at (858) 500-8800 or via email at [email protected].


This page was last updated on 1/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.